Tafamidis soft gelatin capsules 20 mg and 61 mg product-specific bioequivalence guidance HumanScientific guidelines
Page contentsPage contents Open consultation Keywords: Bioequivalence, generics, tafamidis Open consultation Tafamidis soft gelatin capsules 20 mg and 61 mg product-specific bioequivalence guidanceDraft: consultation open Consultation dates: 30/04/2026 to 31/07/2026 Reference Number: EMA/85747/2026 Summary: Comments should be provided using this EU Survey form. For any technical issues, please contact the EUSurvey Support. English (EN) (148.36 KB - PDF)First published: 30/04/2026 View Share this page